• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Clinical Insights on "Tolerability and Effectiveness of Glucagon‑Like Peptide‑1 Receptor Agonists in Patients with Inflammatory Bowel Disease".

作者信息

Yang XiRui, Xie FengJie

机构信息

First Clinical Medical College, Mudanjiang Medical University, Mudanjiang, China.

Department of Intensive Care Unit, Hongqi Hospital Affiliated to Mudanjiang Medical University, Mudanjiang, China.

出版信息

Dig Dis Sci. 2025 Sep 6. doi: 10.1007/s10620-025-09349-5.

DOI:10.1007/s10620-025-09349-5
PMID:40913722
Abstract
摘要

相似文献

1
Clinical Insights on "Tolerability and Effectiveness of Glucagon‑Like Peptide‑1 Receptor Agonists in Patients with Inflammatory Bowel Disease".关于“胰高血糖素样肽-1受体激动剂在炎症性肠病患者中的耐受性和有效性”的临床见解
Dig Dis Sci. 2025 Sep 6. doi: 10.1007/s10620-025-09349-5.
2
Tolerability and Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Inflammatory Bowel Disease.胰高血糖素样肽-1受体激动剂在炎症性肠病患者中的耐受性和有效性
Dig Dis Sci. 2025 Mar 11. doi: 10.1007/s10620-025-08964-6.
3
Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease.用于治疗炎症性肠病风湿性表现的选择性环氧化酶2抑制剂的耐受性
Cochrane Database Syst Rev. 2014 Oct 23;2014(10):CD007744. doi: 10.1002/14651858.CD007744.pub2.
4
Tegaserod for the treatment of irritable bowel syndrome and chronic constipation.替加色罗用于治疗肠易激综合征和慢性便秘。
Cochrane Database Syst Rev. 2007 Oct 17(4):CD003960. doi: 10.1002/14651858.CD003960.pub3.
5
Effectiveness and Safety of Adalimumab in Patients With Very Early-Onset Inflammatory Bowel Disease: A Retrospective Study on Behalf of the Porto Inflammatory Bowel Disease Working Group of European Society for Pediatric Gastroenterology Hepatology and Nutrition.
Inflamm Bowel Dis. 2025 Aug 1;31(8):2184-2194. doi: 10.1093/ibd/izae302.
6
Glucagonlike Peptide-1 Receptor Imaging in Individuals with Type 2 Diabetes.2 型糖尿病患者胰高血糖素样肽-1 受体成像。
J Nucl Med. 2022 May;63(5):794-800. doi: 10.2967/jnumed.121.262506. Epub 2021 Sep 9.
7
The quantity, quality and findings of network meta-analyses evaluating the effectiveness of GLP-1 RAs for weight loss: a scoping review.评估胰高血糖素样肽-1受体激动剂（GLP-1 RAs）减肥效果的网状Meta分析的数量、质量及结果：一项范围综述
Health Technol Assess. 2025 Jun 25:1-73. doi: 10.3310/SKHT8119.
8
Effect of psychological therapy on disease activity, psychological comorbidity, and quality of life in inflammatory bowel disease: a systematic review and meta-analysis.心理疗法对炎症性肠病的疾病活动、心理共病和生活质量的影响：系统评价和荟萃分析。
Lancet Gastroenterol Hepatol. 2017 Mar;2(3):189-199. doi: 10.1016/S2468-1253(16)30206-0. Epub 2017 Jan 18.
9
Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials.罗匹尼罗与其他多巴胺激动剂和左旋多巴治疗帕金森病的耐受性和安全性：随机对照试验的荟萃分析。
Drug Saf. 2010 Feb 1;33(2):147-61. doi: 10.2165/11319860-000000000-00000.
10
Cost-effectiveness Analysis of Subcutaneous Infliximab for Inflammatory Bowel Diseases in Sequential Biologic Treatment.生物序贯治疗中皮下注射英夫利昔单抗治疗炎症性肠病的成本效果分析。
Inflamm Bowel Dis. 2023 Jun 1;29(6):898-913. doi: 10.1093/ibd/izac160.

本文引用的文献

1
Tolerability and Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Inflammatory Bowel Disease.胰高血糖素样肽-1受体激动剂在炎症性肠病患者中的耐受性和有效性
Dig Dis Sci. 2025 Mar 11. doi: 10.1007/s10620-025-08964-6.
2
GLP-1 receptor agonists alleviate colonic inflammation by modulating intestinal microbiota and the function of group 3 innate lymphoid cells.GLP-1 受体激动剂通过调节肠道微生物群和第三类固有淋巴细胞的功能来缓解结肠炎症。
Immunology. 2024 Jul;172(3):451-468. doi: 10.1111/imm.13784. Epub 2024 Mar 27.
3
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
司美格鲁肽在肥胖但无糖尿病患者中的心血管结局。
N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov 11.
4
Correlation of fecal calprotectin and patient-reported outcome measures in patients with ulcerative colitis.溃疡性结肠炎患者粪便钙卫蛋白与患者报告结局指标的相关性
Intest Res. 2022 Apr;20(2):269-273. doi: 10.5217/ir.2021.00064. Epub 2022 Feb 8.
5
Colonic Phenotypes Are Associated with Poorer Response to Anti-TNF Therapies in Patients with IBD.结直肠表型与 IBD 患者对 TNF 拮抗剂治疗的反应较差相关。
Inflamm Bowel Dis. 2017 Aug;23(8):1382-1393. doi: 10.1097/MIB.0000000000001150.